


CLAIMS

1. A pharmaceutically acceptable salt of a compound of formula (Ia):



(Ia),

wherein the pharmaceutically acceptable salt is a citric acid (citrate) salt, a methanesulfonic acid (mesylate) salt, a sulfuric acid (hydrosulfate) salt, a saccharin (saccharinate) salt or an oxalic acid (oxalate) salt.

2. A crystalline form of the pharmaceutically acceptable salt of claim 1 wherein the pharmaceutically acceptable salt is (2R,5S)-7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one citric acid (citrate) salt (E1).

3. The crystalline form of claim 2, having an XRPD pattern with peaks at 2θ values $15.2\pm0.2^\circ$, $23.7\pm0.2^\circ$ and $24.8\pm0.2^\circ$.

4. The crystalline form of claim 2, having an XRPD pattern with peaks at 2θ values $12.0\pm0.2^\circ$, $15.2\pm0.2^\circ$, $15.7\pm0.2^\circ$, $21.7\pm0.2^\circ$, $23.7\pm0.2^\circ$ and $24.8\pm0.2^\circ$.

5. The crystalline form of claim 2, having an XRPD pattern substantially as shown in FIG. 1.

6. A crystalline form of the pharmaceutically acceptable salt-of claim 1, wherein the pharmaceutically acceptable salt is (2R,5S)-7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-

phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one methanesulfonic acid (mesylate) salt (E2).

7. The crystalline form of claim 6, having an XRPD pattern with peaks at 2θ values $17.9\pm0.2^\circ$, $24.5\pm0.2^\circ$ and $26.3\pm0.2^\circ$.

8. The crystalline form of claim 6, having an XRPD pattern with peaks at 2θ values $15.8\pm0.2^\circ$, $17.9\pm0.2^\circ$, $19.1\pm0.2^\circ$, $24.5\pm0.2^\circ$, $25.1\pm0.2^\circ$ and $26.3\pm0.2^\circ$.

9. The crystalline form of claim 6, having an XRPD pattern substantially as shown in FIG. 3.

10. A crystalline form of the pharmaceutically acceptable salt of claim 1, wherein the pharmaceutically acceptable salt is (2R,5S)-7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one sulfuric acid (hydrosulfate) salt (E3).

11. The crystalline form of claim 10, having an XRPD pattern with peaks at four or more 2θ values chosen from $8.1\pm0.2^\circ$, $12.6\pm0.2^\circ$, $14.3\pm0.2^\circ$, $16.5\pm0.2^\circ$, $18.5\pm0.2^\circ$, and $24.8\pm0.2^\circ$.

12. The crystalline form of claim 10, having an XRPD pattern with peaks at five or more 2θ values chosen from $7.8\pm0.2^\circ$, $8.1\pm0.2^\circ$, $12.6\pm0.2^\circ$, $14.3\pm0.2^\circ$, $16.5\pm0.2^\circ$, $18.5\pm0.2^\circ$, $19.6\pm0.2^\circ$, $24.8\pm0.2^\circ$ and $25.3\pm0.2^\circ$.

13. The crystalline form of claim 10, having an XRPD pattern substantially as shown in FIG. 5B.

14. A crystalline form of the pharmaceutically acceptable salt of claim 1, wherein the pharmaceutically acceptable salt is (2R,5S)-7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one saccharin (saccharinate) salt (E5).

15. The crystalline form of claim 14, having 2θ values $6.4\pm0.2^\circ$, $12.8\pm0.2^\circ$ and $15.4\pm0.2^\circ$.

16. The crystalline form of claim 14, having 2θ values $6.4\pm0.2^\circ$, $7.7\pm0.2^\circ$, $12.8\pm0.2^\circ$, $15.4\pm0.2^\circ$, $19.8\pm0.2^\circ$ and $26.3\pm0.2^\circ$.
17. The crystalline form of claim 14, having an XRPD pattern substantially as shown in FIG. 7.
18. A crystalline form of the pharmaceutically acceptable salt of claim 1, wherein the pharmaceutically acceptable salt is (2R,5S)-7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one oxalic acid (oxalate) salt (E6).
19. The crystalline form of claim 18, having an XRPD pattern with peaks at 2θ values $7.9\pm0.2^\circ$, $16.0\pm0.2^\circ$ and $16.7\pm0.2^\circ$.
20. The crystalline form of claim 18, having an XRPD pattern with peaks at 2θ values $7.9\pm0.2^\circ$, $14.8\pm0.2^\circ$, $16.0\pm0.2^\circ$, $16.7\pm0.2^\circ$, $17.8\pm0.2^\circ$, $24.3\pm0.2^\circ$ and $26.4\pm0.2^\circ$.
21. The crystalline form of claim 18, having an XRPD pattern substantially as shown in FIG. 8.
22. A crystalline form of (2R,5S)-7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one (E4).
23. The crystalline form of claim 22, having an XRPD pattern with peaks at 2θ values $4.1\pm0.2^\circ$, $17.0\pm0.2^\circ$, and $22.5\pm0.2^\circ$.
24. The crystalline form of claim 22, having an XRPD pattern with peaks at 2θ values $4.1\pm0.2^\circ$, $12.5\pm0.2^\circ$, $14.9\pm0.2^\circ$, $17.0\pm0.2^\circ$, $20.8\pm0.2^\circ$ and $22.5\pm0.2^\circ$.
25. The crystalline form of claim 22, having an XRPD pattern substantially as shown in FIG. 6.

26. A pharmaceutical composition comprising the pharmaceutically acceptable salt of claim 1 or the crystalline form of claims 2-26, and one or more pharmaceutically acceptable carrier(s), diluents(s) and/or excipient(s).

27. The pharmaceutically acceptable salt of claim 1 or the crystalline form of claims 2-26 for use in the treatment of a disease or condition mediated by modulation of voltage-gated sodium channels.